Glucocorticoid induced osteopenia in cancellous bone of sheep: Validation of large animal model for spine fusion and biomaterial research

Spine

Volumn 35, Issue 4, 2010, Pages 363-370

  Ding, Ming ^a   Cheng, Liming ^a   Bollen, Peter ^b   Schwarz, Peter ^c   Overgaard, Søren ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biomarker; Glucocorticoid induced osteoporosis; Mechanical property; Microarchitecture; Sheep model; Spine fusion

Indexed keywords

CALCIUM; OSTEOCALCIN; PHOSPHORUS; PREDNISOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE ATROPHY; BONE MATURATION; BONE STRENGTH; CALCIUM INTAKE; CANCELLOUS BONE; CONTROLLED STUDY; DIET RESTRICTION; DRUG INDUCED DISEASE; FEMALE; FEMUR; FOLLOW UP; GLUCOCORTICOID INDUCED OSTEOPENIA; LUMBAR VERTEBRA; NONHUMAN; OSTEOPENIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHEEP; SPINE FUSION; TIBIA; TRABECULAR BONE;

ALKALINE PHOSPHATASE; ANIMALS; BIOCOMPATIBLE MATERIALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DISEASES, METABOLIC; CALCIUM; CALCIUM, DIETARY; COLLAGEN; DISEASE MODELS, ANIMAL; FEMALE; FEMUR; GLUCOCORTICOIDS; LUMBAR VERTEBRAE; MATERIALS TESTING; OSTEOCALCIN; PEPTIDE FRAGMENTS; PHOSPHORUS; PHOSPHORUS, DIETARY; PREDNISOLONE; SPINAL FUSION; STRESS, MECHANICAL; TIBIA; TIME FACTORS; X-RAY MICROTOMOGRAPHY;

EID: 77249099402     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181b8e0ff     Document Type: Article

References (31)

1. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-36.
2. Thorndike EA, Turner AS. In search of an animal model for postmenopausal diseases. Front Biosci 1998;3:c17-26.
3. Food and Drug Administration. Guidelines for Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis. Rockville, MD: Division of Metabolism and Endocrine Drug Products; 1994.
4. Egermann M, Goldhahn J, Schneider E. Animal models for fracture treatment in osteoporosis. Osteoporos Int 2005;16(suppl 2):S129-38.
5. Chavassieux P, Pastoureau P, Chapuy MC, et al. Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study. Osteoporos Int 1993;3:97-102.
6. Ross PD. Osteoporosis. Frequency, consequences, and risk factors. Arch Intern Med 1996;156:1399-411.
7. Geusens P, Boonen S, Nijs J, et al. Effect of salmon calcitonin on femoral bone quality in adult ovariectomized ewes. Calcif Tissue Int 1996;59:315-20.
8. Augat P, Schorlemmer S, Gohl C, et al. Glucocorticoid-treated sheep as a model for osteopenic trabecular bone in biomaterials research. J Biomed Mater Res 2003;66A:457-62.
9. Sigrist IM, Gerhardt C, Alini M, et al. The long-term effects of ovariectomy on bone metabolism in sheep. J. Bone Miner Metab 2007;25:28-35.
10. Lill CA, Gerlach UV, Eckhardt C, et al. Bone changes due to glucocorticoid application in an ovariectomized animal model for fracture treatment in osteoporosis. Osteoporos Int 2002;13:407-14.
11. Lill CA, Fluegel AK, Schneider E. Effect of ovariectomy, malnutrition and glucocorticoid application on bone properties in sheep: a pilot study. Osteoporos Int 2002;13:480-6.
12. Schorlemmer S, Gohl C, Iwabu S, et al. Glucocorticoid treatment of ovariectomized sheep affects mineral density, structure, and mechanical properties of cancellous bone. J Bone Miner Res 2003;18:2010-5.
13. Turner AS, Alvis M, Myers W, et al. Changes in bone mineral density and bone-specific alkaline phosphatase in ovariectomized ewes. Bone 1995;17: 395S-402.
14. Leung KS, Siu WS, Cheung NM, et al. Goats as an osteopenic animal model. J Bone Miner Res 2001;16:2348-55.
15. Ding M, Day JS, Burr DB, et al. Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates. Calcif Tissue Int 2003;72:737-44.
16. Ding M, Odgaard A, Linde F, et al. Age-related variations in the microstructure of human tibial cancellous bone. J Orthop Res 2002;20:615-21.
17. Ding M, Odgaard A, Hvid I. Accuracy of cancellous bone volume fraction measured by micro-CT scanning. J Biomech 1999;32:323-6.
18. Ding M, Danielsen CC, Hvid I. Age-related three-dimensional microarchitectural adaptations of subchondral bone tissues in guinea pig primary osteoarthrosis. Calcif Tissue Int 2006;78:113-22.
19. Hildebrand T, Rüegsegger P. A new method for the model-independent assessment of thickness in three-dimensional images. J Micro 1997;185:67-75.
20. Hildebrand T, Rüegsegger P. Quantification of bone microarchitecture with the structure model index. CMBBE 1997;1:15-23.
21. Odgaard A. Three-dimensional methods for quantification of cancellous bone architecture. Bone 1997;20:315-28.
22. Ding M, Dalstra M, Danielsen CC, et al. Age variations in the properties of human tibial trabecular bone. J Bone Joint Surg Br 1997;79:995-1002.
23. Hildebrand T, Laib A, Muller R, et al. Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 1999;14:1167-74.
24. Laan RF, Buijs WC, van Erning LJ, et al. Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content. Calcif Tissue Int 1993;52:5-9.
25. Schorlemmer S, Ignatius A, Claes L, et al. Inhibition of cortical and cancellous bone formation in glucocorticoid-treated OVX sheep. Bone 2005;37: 491-6.
26. Amling M, Herden S, Posl M, et al. Heterogeneity of the skeleton: comparison of the trabecular microarchitecture of the spine, the iliac crest, the femur, and the calcaneus. J Bone Miner Res 1996;11:36-45.
27. Mosekilde Li, Mosekilde Le, Danielsen CC. Biomechanical competence of vertebral trabecular bone in relation to ash density and age in normal individuals. Bone 1987;8:79-85.
28. O'Connell SL, Tresham J, Fortune CL, et al. Effects of prednisolone and deflazacort on osteocalcin metabolism in sheep. Calcif Tissue Int 1993;53: 117-21.
29. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000;21:115-37.
30. Egermann M, Goldhahn J, Holz R, et al. A sheep model for fracture treatment in osteoporosis: benefits of the model versus animal welfare. Lab Anim 2008;42:453-64.
31. Zarrinkalam MR, Beard H, Schultz CG, et al. Validation of the sheep as a large animal model for the study of vertebral osteoporosis. Eur Spine J 2009;18:244-53.